AOD-9604 for Weight Loss: Evidence and FDA Status

AOD-9604 is often discussed as a peptide for fat loss, but it is not an FDA-approved weight-loss medicine. Its larger controlled obesity trial did not show a statistically significant weight-loss advantage over placebo. The FDA’s evaluation of AOD-9604 evidence  helps explain why a promising biological idea has not become a proven obesity treatment.

For Los Angeles readers comparing peptide treatments, the useful questions are specific: what was actually tested in people, did it work better than the comparison treatment, and does that research apply to the product being offered?

What is AOD-9604?

AOD-9604 is a synthetic peptide based on a small portion of human growth hormone. Researchers developed it to investigate effects on fat metabolism. It is a different molecule from complete growth hormone; describing it as a fragment does not establish that it shares all of that hormone’s benefits or risks.

An original AOD-9604 study in obese rats  reported changes in fat metabolism and reduced body-weight gain. Those results supported further investigation. They do not describe weight loss in adults, and reduced weight gain in a growing animal should not be presented as a percentage of body fat that patients can expect to lose.

What do human studies tell us?

Human research exists, so saying AOD-9604 has never been studied in people would be inaccurate. A 2013 report of AOD-9604 human safety studies  summarized six trials, including brief intravenous experiments and longer oral studies. Its main purpose was to describe safety and tolerability.

The authors reported reassuring findings for several measured safety outcomes under those study conditions. The trials were funded by the developer, and the paper disclosed author financial or consulting relationships with that company. These relationships deserve consideration when reading the conclusions; they do not automatically invalidate the data.

The larger obesity trial did not establish effectiveness

In the 24-week OPTIONS trial, 502 adults were randomized to oral AOD-9604 or placebo alongside a supervised diet and exercise program. FDA’s assessment describes no statistically significant weight-loss difference at the 12-week primary endpoint or at 24 weeks. The sponsor stopped development for obesity in 2007.

People losing weight during a trial does not, by itself, show that the study medicine caused the improvement. The important comparison is whether the medicine added a meaningful benefit over the control group receiving the same background care.

Oral findings do not establish injectable benefits

The larger obesity trial tested an oral product. FDA’s review did not identify human evidence for the proposed subcutaneous or transdermal preparations. Brief intravenous studies also cannot establish the benefit or long-term safety of repeated injections under the skin.

Changing the route is a new clinical question, not a way to assume a favorable result. Ask for research that matches the exact compound, formulation, route, and intended outcome. A laboratory explanation of fat metabolism is not a substitute for that evidence.

Is AOD-9604 FDA-approved?

AOD-9604 has no FDA-approved weight-loss indication. A prescription, a pharmacy label, or the fact that other peptide medicines are approved does not give AOD-9604 its own approval. Approval and the assessment of ingredients for compounding are separate processes.

What the compounding review means

The December 2024 advisory committee’s final minutes  record a unanimous 12-to-0 vote against placing AOD-9604 free base and AOD-9604 acetate on the 503A Bulks List for the obesity use evaluated. That was a compounding-list recommendation, not a drug-approval decision or a blanket statement about every legal circumstance.

FDA’s current framework for 503A bulk substances  sets conditions for using ingredients in pharmacy compounding. Do not assume that an old nomination, a change in an interim category, or online availability establishes a lawful pathway for a particular preparation. Ask the prescriber and dispensing pharmacist to explain its current basis.

More generally, FDA information on compounded drug risks  explains that compounded medicines are not FDA-approved and do not receive the agency’s premarket review for safety, effectiveness, or quality.

What safety questions remain?

The FDA’s current AOD-9604 safety entry  appears under bulk substances whose nominations were withdrawn. It identifies limited safety information, potential immune-response risks for certain routes, and challenges involving peptide impurities and characterization of the active ingredient. It also notes serious adverse events that may be associated with AOD-9604, while making clear that causation is uncertain.

That uncertainty should be preserved. The record does not justify saying AOD-9604 caused every reported event, or promising that it has no serious risks. Short-term tolerability findings for one preparation do not settle the safety of another preparation or prolonged use.

Build a weight-management plan around your health

Before paying for an experimental treatment, discuss your weight history, health conditions, medicines, goals, and previous attempts with a clinician. The NIH’s guidance on prescription weight-management medicines  describes treatment as an individualized decision that considers potential benefits, side effects, other medicines, and cost. Approved medicines support an eating and activity plan rather than replacing it.

A useful consultation should also make the evidence understandable. Ask what improvement would count as meaningful, how progress would be measured, and how the plan would change if benefits did not appear. If someone recommends AOD-9604, ask why it is being considered instead of options with established evidence for your medical situation.

You should leave knowing which claims come from controlled human research and which remain hypotheses. A persuasive testimonial cannot tell you what would have happened without the treatment.

Frequently asked questions

Does AOD-9604 work for weight loss?

Current evidence does not establish it as an effective obesity treatment. The larger oral trial failed to show a significant advantage over placebo, and evidence for the proposed injectable use is lacking.

Can AOD-9604 target belly fat?

There is no established clinical basis for promising targeted belly-fat reduction. An animal fat-metabolism finding does not demonstrate that effect in patients receiving an injection.

Does a compounded prescription mean FDA approval?

No. Compounding and approval are different questions. Ask about the exact preparation’s regulatory basis, quality safeguards, and clinical evidence.

Is AOD-9604 simply a safer form of growth hormone?

That description goes beyond the evidence. It is a different peptide, and reassuring observations in limited studies cannot guarantee safety for every formulation, route, or patient.

Bring the evidence questions to your visit

If you are exploring peptide therapy in Los Angeles , bring the product name and the claims you have seen to your appointment. You can contact SoCal Testosterone Clinic  to discuss treatment questions and your health goals. An informed conversation should cover established options, remaining uncertainties, and what fits your individual medical needs.